Findings

What do systematic reviews say?

33 questions · 33 findings · 6 reviews · Cystic Fibrosis and Genetic Disorders

Sort:Best matchNewest Highest certainty Download CSV

No studies found 9 · 27.3%GRADE not reported 0 · 0%Very low 9 · 27.3%Low 5 · 15.2%Moderate 7 · 21.2%High 3 · 9.1%

Intravenous ceftazidime with tobramycin vs ciprofloxacin

Adverse effects of antibiotics · adults and children with cystic fibrosis and a positive microbiological isolate of P aeruginosa from a respiratory tract specimen

Intravenous ceftazidime with tobramycin probably leads to lower adverse effects of antibiotics: compared with oral ciprofloxacin (moderate certainty).

1 finding from 1 review

Antibiotic strategies for eradicating Pseudomonas aeruginosa in people with cystic fibrosis 2023 · Cochrane Headline outcomes only
RR 0.97
1 study · 285 participants
Moderate

Oral azithromycin vs placebo

FEV1 % predicted: absolute change from baseline · adults and children with cystic fibrosis

1 finding from 1 review

Macrolide antibiotics (including azithromycin) for cystic fibrosis 2024 · Cochrane Headline outcomes only
no estimate extracted
4 studies · 549 participants
High

Oral azithromycin vs placebo

Time to next pulmonary exacerbation · adults and children with cystic fibrosis

1 finding from 1 review

Macrolide antibiotics (including azithromycin) for cystic fibrosis 2024 · Cochrane Headline outcomes only
no estimate extracted
4 studies · 796 participants
Moderate

Oral azithromycin vs placebo

Adverse events: number of mild treatment‐related adverse events · adults and children with cystic fibrosis

1 finding from 1 review

Macrolide antibiotics (including azithromycin) for cystic fibrosis 2024 · Cochrane Headline outcomes only
no estimate extracted
4 studies · 748 participants
Moderate

Oral azithromycin vs placebo

Hospital admissions · adults and children with cystic fibrosis

1 finding from 1 review

Macrolide antibiotics (including azithromycin) for cystic fibrosis 2024 · Cochrane Headline outcomes only
no estimate extracted
2 studies · 445 participants
High

Oral azithromycin vs placebo

New acquisition of CF pathogens: PA · adults and children with cystic fibrosis

1 finding from 1 review

Macrolide antibiotics (including azithromycin) for cystic fibrosis 2024 · Cochrane Headline outcomes only
no estimate extracted
2 studies · 282 participants
Moderate

Oral azithromycin vs placebo

QoL · adults and children with cystic fibrosis

1 finding from 1 review

Macrolide antibiotics (including azithromycin) for cystic fibrosis 2024 · Cochrane Headline outcomes only
no estimate extracted
1 study · 177 participants
Moderate

Summary of findings ‐ nebulised azithromycin vs azithromycin

FEV1 % predicted: absolute change from baseline · children with cystic fibrosis

1 finding from 1 review

Macrolide antibiotics (including azithromycin) for cystic fibrosis 2024 · Cochrane Headline outcomes only
no estimate extracted
1 study · 45 participants
Very low

Summary of findings ‐ nebulised azithromycin vs azithromycin

Time to next pulmonary exacerbation · children with cystic fibrosis

The review found no eligible studies for this question.

1 finding from 1 review

Macrolide antibiotics (including azithromycin) for cystic fibrosis 2024 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Summary of findings ‐ nebulised azithromycin vs azithromycin

Adverse events: number of treatment‐related adverse events · children with cystic fibrosis

1 finding from 1 review

Macrolide antibiotics (including azithromycin) for cystic fibrosis 2024 · Cochrane Headline outcomes only
no estimate extracted
1 study · 45 participants
Very low

Summary of findings ‐ nebulised azithromycin vs azithromycin

Hospital admissions · children with cystic fibrosis

The review found no eligible studies for this question.

1 finding from 1 review

Macrolide antibiotics (including azithromycin) for cystic fibrosis 2024 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Summary of findings ‐ nebulised azithromycin vs azithromycin

New acquisition of CF pathogens: PA (mean change in PA count (log10 PA CFU/g sputum)) · children with cystic fibrosis

1 finding from 1 review

Macrolide antibiotics (including azithromycin) for cystic fibrosis 2024 · Cochrane Headline outcomes only
no estimate extracted
1 study · 45 participants
Very low

Summary of findings ‐ nebulised azithromycin vs azithromycin

QoL · children with cystic fibrosis

1 finding from 1 review

Macrolide antibiotics (including azithromycin) for cystic fibrosis 2024 · Cochrane Headline outcomes only
no estimate extracted
1 study · 45 participants
Very low